HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation

نویسندگان

  • Anne-lie Ståhl
  • Fariba Vaziri-Sani
  • Stefan Heinen
  • Ann-Charlotte Kristoffersson
  • Karl-Henrik Gydell
  • Reem Raafat
  • Alberto Gutierrez
  • Ortraud Beringer
  • Peter F. Zipfel
  • Diana Karpman
چکیده

1Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden; 2Department of Biological Infection, Hans Knoell Institute for Natural Products Research, Jena, Germany; 3Department of Internal Medicine, Regional Hospital, Halmstad, Sweden; 4Department of Pediatric Nephrology, University of Texas Health Science Center at San Antonio, TX; 5Division of Renal Medicine, Karolinska University Hospital, Stockholm, Sweden; 6Children’s University Hospital, Tübingen, Germany; and 7Friedrich Schiller University, Jena, Germany

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis

BACKGROUND Vascular endothelial cells (ECs) express and release protein components of the complement pathways, as well as secreting and anchoring ultra-large von Willebrand factor (ULVWF) multimers in long string-like structures that initiate platelet adhesion during hemostasis and thrombosis. The alternative complement pathway (AP) is an important non-antibody-requiring host defense system. Th...

متن کامل

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease characterized by uncontrolled complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage. We evaluated the effect of terminal complement blockade with the anti-C5 monoclonal antibody eculizumab on biomarkers of cellular processes involved in TMA in patients with aHUS longitudinally, du...

متن کامل

Complement activation in thrombotic microangiopathy.

The endothelium lining the vascular lumen is continuously exposed to complement from the circulation. When erroneously activated on host cells, complement may generate a deleterious effect on the vascular wall leading to endothelial injury, exposure of the subendothelial matrix and platelet activation. In this review the contribution of complement activation to formation and maintenance of the ...

متن کامل

Komplementaktivierung bei thrombotischer Mikroangiopathie

The endothelium lining the vascular lumen is continuously exposed to complement from the circulation. When erroneously activated on host cells, complement may generate a deleterious effect on the vascular wall leading to endothelial injury, exposure of the subendothelial matrix and platelet activation. In this review the contribution of complement activation to formation and maintenance of the ...

متن کامل

Cutaneous thrombogenic vasculopathy associated with bevacizumab therapy.

Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is an angiogenesis inhibitor used to treat a variety of cancers, including lung, colon, cervical, ovarian, and renal cancers as well as glioblastoma. A significant adverse effect associated with its use is one of thromboembolic events. We report a case of a 74-year-old male with diagnosis of glioblas...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2008